Dr. Metzger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800- Is this information wrong?
Education & Training
- Universite Libre de BruxelesPhD, Breast Cancer, 2009 - 2013
- Federal University of Minas GeraisClass of 2003
Certifications & Licensure
- MA State Medical License 2013 - 2025
Awards, Honors, & Recognition
- Clinical Scholar Award San Antonio Breast Cancer Symposium, 2010
Clinical Trials
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) Start of enrollment: 2016 May 24
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Start of enrollment: 2017 Jun 21
- Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen Start of enrollment: 2007 Dec 15
Publications & Presentations
PubMed
- Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.Guerriero, J., Lin, J., Pastorello, R., Du, Z., Chen, Y., Townsend, M., Shimada, K., Hughes, M., Ren, S., Tayob, N., Zheng, K., Mei, S., Patterson, A., Taneja, K., Met...> ;NPJ Breast Cancer. 2024 Jan 2
- Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma.Tae In Yoon, Joon Jeong, Seokwon Lee, Jai Min Ryu, Young Joo Lee, Jee Yeon Lee, Ki-Tae Hwang, Hakyoung Kim, Seonok Kim, Sae Byul Lee, Beom Seok Ko, Jong Won Lee, Byung...> ;JAMA Network Open. 2023 Nov 1
- 1 citationsEndocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.Francisco Hermida-Prado, Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi, Zhengtao Chu, Avery Feit, Marco Campisi, Minyue Chen, Agostina Nardon...> ;Cancer Research. 2023 Oct 2
- Join now to see all
Journal Articles
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first line trastuzu...Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU, Clin Breast Cancer, 8/1/2013
- The magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA trialMetzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R..., J Clin Oncol, 6/1/2013
- Analysis of Regional Timelines to Set up a Global Phase III Clinical Trial in Breast Cancer: The ALTTO ExperienceMetzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu ..., Oncologist, 1/1/2013
- Join now to see all
Lectures
- Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.2019 ASCO Annual Meeting - 6/1/2019
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Gene Signature May Be Similarly Prognostic in ILC and IDCOctober 20th, 2020
- Patients with Invasive Lobular Carcinoma Could Benefit from Additional Adjuvant TherapyOctober 1st, 2020
- Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast CancerAugust 22nd, 2017
- Join now to see all
Professional Memberships
- Member
Other Languages
- Portuguese, French
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: